| Business Summary | | Cytomedix
Inc.
develops,
produces,
licenses
and
distributes
cellular
therapies
for
the
treatment
of
wounds.
At
present,
the
Company
offers
two
growth
factor
therapies
for
the
treatment
of
chronic,
non-healing
wounds:
Procuren
and
the
AuTolo-Gel
process.
Both
therapies
are
centered
on
harvesting
and
activating
a
patient's
own
platelets
to
isolate
and
release
the
growth
factors
contained
in
the
platelets.
The
Procuren
product
and
platelet
gel
made
using
the
AuTolo-Gel
process
are
designed
to
stimulate
and
accelerate
a
normal
wound
healing
response
in
much
the
same
way
a
healthy
body
naturally
initiates
healing. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | CYDXE
is
engage
in
the
development,
sale
and
marketing
of
a
proprietary
system,
known
as
the
AuTolo-Cure
(TM)
System,
for
the
treatment
of
chronic,
non-healing
wounds.
For
the
three
months
ended
3/31/01,
revenues
totaled
$1.2
million,
up
from
$35
thousand.
Net
loss
applicable
to
Common
rose
3%
to
$6.7
million.
Revenues
benefited
from
sales
to
Curative
Health
Services.
Higher
loss
reflects
the
issuance
of
warrants
to
acquire
Cytomedix
stock
and
warrants
issued
to
3rd
party
consultants. | More
from
Market Guide: Significant
Developments |
| Officers | |
| Position | James Cour | Pres,
CEO, Director | Glenn Charlesworth | VP-Fin.,
CFO | David Demarest | VP,
Sec., Gen. Counsel | Kent Smith | VP
of Sales and Marketing | Robin Geller | VP
of Science and Technology |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|